Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Celebrating a nice-looking chart is much easier than understanding exactly what is making the line change direction.

In November, NVO shares crossed into a long-term bear market as they fell below their 20-month moving average - a key ...

In this article, we will be taking a look at the 12 best weight loss stocks to buy according to hedge funds. The Revolution ...

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

Novo Nordisk's reign as Europe's most valuable company is facing a challenge from US rival Eli Lilly. Lilly's weight-loss ...